Aerie Pharmaceuticals (AERI)

AERI was delisted on the 18th of November, 2022.

• Market cap: $754M
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Employees: 376